Anthony J. Polverino
Director/Board Member at BRAINSTORM CELL THERAPEUTICS INC.
Net worth: 14 667 $ as of 2024-03-30
Profile
Anthony J.
Polverino is an Independent Director at Brainstorm Cell Therapeutics, Inc. He was previously an Executive Director at Amgen, Inc., Chief Scientific Officer at Kite Pharma, Inc., and Chief Scientific Officer & EVP-Early Development at Zymeworks BC, Inc. Polverino received his undergraduate degree from the University of Adelaide and his doctorate from Flinders University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-10-30 | 25,960 ( 0.05% ) | 14 667 $ | 2024-03-30 |
Anthony J. Polverino active positions
| Companies | Position | Start |
|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Director/Board Member | 2018-02-04 |
Former positions of Anthony J. Polverino
| Companies | Position | End |
|---|---|---|
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Chief Tech/Sci/R&D Officer | 2022-01-18 |
| KITE PHARMA INC | Chief Tech/Sci/R&D Officer | 2017-12-31 |
| AMGEN INC. | Corporate Officer/Principal | - |
Training of Anthony J. Polverino
| University of Adelaide | Undergraduate Degree |
| Flinders University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| BRAINSTORM CELL THERAPEUTICS INC. | Health Technology |
| Private companies | 2 |
|---|---|
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
- Stock Market
- Insiders
- Anthony J. Polverino
